- Home
- RQI vs INBX Comparison
RQI vs INBX Comparison
Compare RQI & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RQI | INBX |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2001 | 2024 |
Fundamental Metrics
Financial Performance| Metric | RQI | INBX |
|---|---|---|
| Price | $12.63 | $81.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $150.00 |
| AVG Volume (30 Days) | ★ 912.0K | 295.1K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 8.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $11.30 | $20.55 |
| 52 Week High | $13.57 | $155.29 |
Technical Indicators
Market Signals| Indicator | RQI | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 55.00 | 35.49 |
| Support Level | $12.12 | $71.31 |
| Resistance Level | $13.47 | $85.97 |
| Average True Range (ATR) | 0.15 | 5.92 |
| MACD | 0.05 | -0.98 |
| Stochastic Oscillator | 100.00 | 2.68 |
Price Performance
Historical ComparisonAbout RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. The Fund's secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.